<?xml version='1.0' encoding='utf-8'?>
<document id="29786857"><sentence text="Effect of OATP1B1/1B3 Inhibitor GDC-0810 on the Pharmacokinetics of Pravastatin and Coproporphyrin I/III in Healthy Female Subjects."><entity charOffset="68-79" id="DDI-PubMed.29786857.s1.e0" text="Pravastatin" /><entity charOffset="84-98" id="DDI-PubMed.29786857.s1.e1" text="Coproporphyrin" /><pair ddi="false" e1="DDI-PubMed.29786857.s1.e0" e2="DDI-PubMed.29786857.s1.e0" /><pair ddi="false" e1="DDI-PubMed.29786857.s1.e0" e2="DDI-PubMed.29786857.s1.e1" /></sentence><sentence text="Developed as an oral anticancer drug to treat estrogen receptor-positive breast cancer, GDC-0810 was shown to be a potent inhibitor of organic anion-transporting polypeptide 1B1 and 1B3 (OATP1B1/1B3) from an in vitro assay"><entity charOffset="46-54" id="DDI-PubMed.29786857.s2.e0" text="estrogen" /></sentence><sentence text=" A clinical study was conducted to assess the drug-drug interaction potential between GDC-0810 and pravastatin, which is a relatively selective and sensitive OATP1B1/1B3 substrate"><entity charOffset="99-110" id="DDI-PubMed.29786857.s3.e0" text="pravastatin" /></sentence><sentence text=" Fifteen healthy female subjects of non-childbearing potential were enrolled in the study" /><sentence text=" On day 1 in period 1, a single 10-mg dose of pravastatin was administered to all subjects"><entity charOffset="46-57" id="DDI-PubMed.29786857.s5.e0" text="pravastatin" /></sentence><sentence text=" Following a 4-day washout period, 600 mg of GDC-0810 was administered once daily on days 5 through 8 in period 2 to achieve steady-state concentrations" /><sentence text=" On day 7, a single dose of 10-mg pravastatin was coadministered with the 600-mg GDC-0810 dose"><entity charOffset="34-45" id="DDI-PubMed.29786857.s7.e0" text="pravastatin" /></sentence><sentence text=" Concentrations of pravastatin (periods 1 and 2) and GDC-0810 (period 2 only) were quantified in blood samples and subsequently used to calculate the pharmacokinetics (PK) parameters"><entity charOffset="19-30" id="DDI-PubMed.29786857.s8.e0" text="pravastatin" /><entity charOffset="53-61" id="DDI-PubMed.29786857.s8.e1" text="GDC-0810" /><pair ddi="false" e1="DDI-PubMed.29786857.s8.e0" e2="DDI-PubMed.29786857.s8.e0" /><pair ddi="false" e1="DDI-PubMed.29786857.s8.e0" e2="DDI-PubMed.29786857.s8.e1" /></sentence><sentence text=" The pravastatin mean maximal concentration and area under the curve values were approximately 20% and 41% higher, respectively, following pravastatin coadministration with GDC-0810 compared to pravastatin alone"><entity charOffset="5-16" id="DDI-PubMed.29786857.s9.e0" text="pravastatin" /><entity charOffset="139-150" id="DDI-PubMed.29786857.s9.e1" text="pravastatin" /><entity charOffset="173-181" id="DDI-PubMed.29786857.s9.e2" text="GDC-0810" /><entity charOffset="194-205" id="DDI-PubMed.29786857.s9.e3" text="pravastatin" /><pair ddi="false" e1="DDI-PubMed.29786857.s9.e0" e2="DDI-PubMed.29786857.s9.e0" /><pair ddi="false" e1="DDI-PubMed.29786857.s9.e0" e2="DDI-PubMed.29786857.s9.e1" /><pair ddi="false" e1="DDI-PubMed.29786857.s9.e0" e2="DDI-PubMed.29786857.s9.e2" /><pair ddi="false" e1="DDI-PubMed.29786857.s9.e0" e2="DDI-PubMed.29786857.s9.e3" /><pair ddi="false" e1="DDI-PubMed.29786857.s9.e1" e2="DDI-PubMed.29786857.s9.e1" /><pair ddi="false" e1="DDI-PubMed.29786857.s9.e1" e2="DDI-PubMed.29786857.s9.e2" /><pair ddi="false" e1="DDI-PubMed.29786857.s9.e1" e2="DDI-PubMed.29786857.s9.e3" /><pair ddi="false" e1="DDI-PubMed.29786857.s9.e2" e2="DDI-PubMed.29786857.s9.e2" /><pair ddi="false" e1="DDI-PubMed.29786857.s9.e2" e2="DDI-PubMed.29786857.s9.e3" /></sentence><sentence text=" Based on the magnitude of change in this drug-drug interaction study, dose adjustments for pravastatin (and other OATP1B1/1B3 substrates) were not considered necessary when administered with GDC-0810"><entity charOffset="92-103" id="DDI-PubMed.29786857.s10.e0" text="pravastatin" /></sentence><sentence text=" Retrospectively, the endogenous biomarkers of OATP1B1/1B3, coproporphyrin I and III, were also measured and showed changes comparable to those of pravastatin, indicating their utility in detecting weak inhibition of OATP1B1/1B3 in the clinical setting"><entity charOffset="147-158" id="DDI-PubMed.29786857.s11.e0" text="pravastatin" /></sentence><sentence text="" /></document>